Preferential Estrogen Receptor β Ligands Inhibit Proliferation and Reduce Bcl-2 Expression in Fulvestrant-resistant Breast Cancer Cells
Endocrine resistance is a significant clinical problem in the treatment of estrogen (E2) receptor positive breast cancers. There are two ER subtypes, ERα and ERβ, which promote and inhibit breast cancer cell proliferation respectively. While ER positive breast cancers typically express a high ratio...
| Main Author: | |
|---|---|
| Language: | en |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/23669 |